|
|
MDA-MB-435S
|
|
Biosafety Level: |
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent |
|
|
Homo sapiens (human)
|
|
|
spindle shaped

|
|
|
Organ: previously described as: mammary gland; breast Disease: previously described as ductal carcinoma Derived from metastatic site: pleural effusion |
|
|
tubulin; actin
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
Isolation date: 1976 |
|
|
No
|
|
|
Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 13 D5S818: 12 D7S820: 8,10 THO1: 6,7 TPOX: 8,11 vWA: 16,18 |
|
|
modal number = 56; range = 55 to 62 The cell line is aneuploid human female (XX), with most chromosome counts in the 55 to 60 range. Normal chromosomes N6, N11, and N22 were absent, while chromosomes N7, N13, N18 and N21 were single. Most of the remainder of normal chromosomes were usually paired, but chromosome N2 was triple. Nineteen marker chromosomes were identified, with most of them formed from structural alterations of the missing copies of the normal chromosomes. Six of these markers involve regions of chromosome N7, while three are recognized as derivatives of chromosome N6. Regions of a third copy of the normal and paired chromosomes N3, N15, N17, N20 are noted in markers M1, M2, M15, and M5, respectively. |
|
|
AK-1, 1 ES-D, 1 G6PD, B GLO-I, 2 PGM1, 2 PGM3, 1 |
|
|
31 years adult |
|
|
female |
|
|
Caucasian |
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008.
To make the complete growth medium, add the following components to the base medium:
- 0.01mg/ml bovine insulin
- 0.01mg/ml glutathione
- fetal bovine serum to a final concentration of 10%
Atmosphere: air, 100% Temperature: 37.0°C |
|
|
Protocol: Remove medium, add fresh 0.25%trypsin - 0.53 mM EDTA, rinse and remove. Place flask at room temperature (or incubated at 37C) for approximately 10 minutes or until the cells detach. Add fresh medium, aspirate and dispense into new flasks. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended Medium Renewal: 2 to 3 times per week |
|
|
Freeze medium: Culture medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008 recommended serum:ATCC 30-2020 purified DNA:ATCC HTB-129D purified RNA:ATCC HTB-129R |
|
|
1206: Brinkley BR, et al. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40: 3118-3129, 1980. PubMed: 7000337 22429: Siciliano MJ, et al. Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker. Cancer Res. 39: 919-922, 1979. PubMed: 427779 22656: Cailleau R, et al. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915, 1978. PubMed: 730202 32341: Sheng S, et al. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 93: 11669-11674, 1996. PubMed: 8876194 32925: Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224 49803: Ross DT, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics 24: 227-235, 2000. PubMed: 10700174 89918: Ellison G, et al. Further evidence to support the melanocytic origin of MDA-MB-435. Mol. Pathol. 55: 294-299, 2002. PubMed: 12354931 90826: Sellappan s, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 64: 3479-3485, 2004. PubMed: 15150101 90828: Rae JM, et al. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. Clin. Exp. Metastasis 21: 543-552, 2004. PubMed: 15679052 16173093: Rae JM, et al., MDA-MB-435 cells are derived from M14 Melanoma cells - a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res. Treat. 104:13-19, 2007. PubMed: 17004106. 16173545: Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res. 69(13): 5292-5293, 2009. PubMed: 19549886. |
|
|